Zum Inhalt springen

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — The post Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer appeared first on Bio Tech Winners.

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

Entdecke mehr von LabNews

Melde dich für ein Abonnement an, um die neuesten Beiträge per E-Mail zu erhalten.

Autoren-Avatar
LabNews Media LLC
LabNews: Biotech. Digital Health. Life Sciences. Pugnalom: Environmental News. Nature Conservation. Climate Change. augenauf.blog: Wir beobachten Missstände

Entdecke mehr von LabNews

Jetzt abonnieren, um weiterzulesen und auf das gesamte Archiv zuzugreifen.

Weiterlesen